Abstracts tagged "Adalimumab and juvenile arthritis"

Abstract Number: 764 • 2012 ACR/ARHP Annual Meeting
The Impact of Adalimumab On Growth in Patients with Juvenile Idiopathic Arthritis
D. J. Lovell¹, Nicolino Ruperto², Katerina Jarosova³, Dana Nemcova⁴, Veronika Vargova³, Hartmut Michels³, Elizabeth Chalom⁵, Norman Ilowite⁵, Carine Wouters⁶, Hermine Brunner⁷, Karolyn Kracht⁸, Hartmut Kupper⁹, Edward Giannini⁵, Alberto Martini¹⁰ and Neelufar Mozaffarian¹¹, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, ³PRINTO, Gaslini Institute, Genova, Italy, ⁴Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶PRINTO, Genoa, Italy, ⁷PRCSG, Cincinnati Children’s Hospital Medical Center, Genova, Italy, ⁸Abbott, Abbott, Abbott Park, IL, ⁹Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ¹⁰Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ¹¹Abbott, Abbott Park, IL
Background/Purpose: Children with juvenile idiopathic arthritis (JIA) often exhibit growth impairments. Treatment with adalimumab (ADA) has been shown to be safe and effective in JIA…
Abstract Number: 1148 • 2012 ACR/ARHP Annual Meeting
Adalimumab – Effective Control under Refractory JIA Associated Uveitis
Ekaterina Alekseeva¹, Elena Mitenko², Tatyana Bzarova², Saniya Valieva², Kseniya Isayeva², Alexandra Chomakhidze², Evgeniya Chistyakova², Tatyana Sleptsova² and Rina Denisova², ¹PRINTO, Genoa, Italy, ²Rheumatology, Scientific Center of Children's Health, Moscow, Russia
Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA)–associated uveitis is one of the serious problems of paediatric rheumatology. JIA associated uveitis often is refractory to MTX,…
Abstract Number: 1678 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Adalimumab in Children with Active Polyarticular Juvenile Idiopathic Arthritis Aged 2 to <4 Years or ≥4 Years Weighing <15 Kg
Daniel J. Kingsbury¹, Pierre Quartier², Gina Patel³, Vipin Arora⁴, Hartmut Kupper⁵ and Neelufar Mozaffarian³, ¹Randall Children's Hospital at Legacy Emanuel, Portland, OR, ²Unite d'Immuno-Hematologie et Rhumatologie Pediatriques, Paris, France, ³Abbott, Abbott Park, IL, ⁴Health Outcomes Research, Abbott, Abbott Park, IL, ⁵Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany
Background/Purpose: Adalimumab (ADA) is approved for use in moderate to severe JIA in patients (pts) ≥4 yrs old in the US, EU,and Japan. ADA has…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.